Meeting
2022 ASCO Annual Meeting
CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma.
Authors
Ravi Vij
Washington University, St. Louis, MO
Ravi Vij , Henning Schade , Suzanne Trudel , Alice C. Chang , Jiangeng Huang , Divya Samineni , Teiko Sumiyoshi , Jennifer Tsai , Tiffany Wong , Simon J. Harrison
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT04910568
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS8069)
DOI
10.1200/JCO.2022.40.16_suppl.TPS8069
Abstract #
TPS8069
Poster Bd #
491b
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
GO39775: A multicenter phase I trial evaluating the safety, pharmacokinetics, and activity of BFCR4350A, a FcRH5/CD3 T-cell dependent bispecific antibody, in patients with relapsed or refractory multiple myeloma.
First Author: Adam D. Cohen
Poster
2022 ASCO Annual Meeting
CAMMA 3: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostamab monotherapy in patients with relapsed or refractory multiple myeloma.
First Author: Sosana Delimpasi
Poster
2022 ASCO Annual Meeting
A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
First Author: Andrew J Yee
Poster
2021 ASCO Annual Meeting
Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.
First Author: Cristina Gasparetto